Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice
Main Article Content
Abstract
Background: The potential for promotion of intestinal colonization with healthcare-associated pathogens by new antibiotics used to treat infections due to multidrug-resistant Gram-negative bacilli is unclear.
Methods: Mice treated for 3 days with daily subcutaneous phosphate-buffered saline (control), ceftazidime/avibactam, ceftolozane/tazobactam, ceftaroline, and meropenem/vaborbactam were challenged with 10,000 colony-forming units (CFU) of vancomycin-resistant Enterococcus (VRE) resistant to each of the antibioics or carbapenemase-producing Klebsiella pneumoniae 1 day after the final treatment dose. The concentrations of VRE or K. pneumoniae in stool were measured on days 1, 3, 6, and 15 after challenge.
Results: Control mice had transient low levels of VRE or K. pneumoniae (<3 log10 CFU/g) detected in stool with negative cultures on days 6 and 15 after challenge. In comparison to control mice, each of the antibiotics promoted establishment of high-density colonization with VRE (mean concentration, >8 log10 CFU/g of stool on day 1 after challenge) that persisted at >4 log10 CFU/g of stool through day 15 (P<0.01). In comparison to control mice, meropenem/vaborbactam and ceftaroline promoted high-density colonization with K. pneumoniae (peak concentration, >8 log10 CFU/g of stool) (P<0.01), ceftolozane/tazobactam promoted colonization to a lesser degree (peak concentration, >5 log10 CFU/g of stool), and ceftazidime/avibactam did not promote colonization (P>0.05).
Conclusions: Our results suggest that several beta-lactam antibiotics recently developed for treatment of infections with resistant Gram-negative bacilli have the potential to promote colonization by healthcare-associated pathogens. Additional studies are needed to examine the impact of these agents in patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39(2):219-26. doi: 10.1086/422002. PubMed PMID: 15307031.
2. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343(26):1925-32. doi: 10.1056/NEJM200012283432604. PubMed PMID: 11136263; PMCID: PMC4370337.
3. Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol. 2003;24(9):644-9. doi: 10.1086/502267. PubMed PMID: 14510245.
4. Hoyen CK, Pultz NJ, Paterson DL, Aron DC, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2003;47(11):3610-2. doi: 10.1128/AAC.47.11.3610-3612.2003. PubMed PMID: 14576127; PMCID: PMC253805.
5. Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis. 2006;43 Suppl 2(Supplement_2):S62-9. doi: 10.1086/504481. PubMed PMID: 16894517.
6. Pultz MJ, Donskey CJ. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrob Agents Chemother. 2007;51(8):3044-5. doi: 10.1128/AAC.00194-07. PubMed PMID: 17562802; PMCID: PMC1932530.
7. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55 Suppl 2(Suppl 2):S121-6. doi: 10.1093/cid/cis440. PubMed PMID: 22752860; PMCID: PMC3388028.
8. Xu D, Mana TSC, Cadnum JL, Deshpande A, Afsari F, Sangwan N, Donskey CJ. Why Does Doxycycline Pose a Relatively Low Risk for Promotion of Clostridioides difficile Infection? Pathog Immun. 2022;7(1):81-94. doi: 10.20411/pai.v7i1.512. PubMed PMID: 35800258; PMCID: PMC9254868.
9. Stiefel U, Pultz NJ, Helfand MS, Donskey CJ. Increased susceptibility to vancomycin-resistant Enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect Control Hosp Epidemiol. 2004;25(5):373-9. doi: 10.1086/502408. PubMed PMID: 15188841.
10. Abujamel T, Cadnum JL, Jury LA, Sunkesula VC, Kundrapu S, Jump RL, Stintzi AC, Donskey CJ. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One. 2013;8(10):e76269. doi: 10.1371/journal.pone.0076269. PubMed PMID: 24098459; PMCID: PMC3788714.
11. Donskey CJ, Kundrapu S, Deshpande A. Colonization versus carriage of Clostridium difficile. Infect Dis Clin North Am. 2015;29(1):13-28. doi: 10.1016/j.idc.2014.11.001. PubMed PMID: 25595843.
12. Munoz KA, Ulrich RJ, Vasan AK, Sinclair M, Wen PC, Holmes JR, Lee HY, Hung CC, Fields CJ, Tajkhorshid E, Lau GW, Hergenrother PJ. A Gram-negative-selective antibiotic that spares the gut microbiome. Nature. 2024;630(8016):429-36. doi: 10.1038/s41586-024-07502-0. PubMed PMID: 38811738.
13. Shirley DA, Heil EL, Johnson JK. Ceftaroline fosamil: a brief clinical review. Infect Dis Ther. 2013;2(2):95-110. doi: 10.1007/s40121-013-0010-x. PubMed PMID: 25134474; PMCID: PMC4108109.
14. Mosley JF, 2nd, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections. P T. 2016;41(8):479-83. PubMed PMID: 27504064; PMCID: PMC4959616.
15. Meropenem/vaborbactam (Rx) Medscape: Medscape. Available from: https://reference.medscape.com/drug/vabomere-meropenem-vaborbactam-1000130#0.
16. Ceftolozane/tazobactam (CXA-101). : Center for Drug Evaluation and Research, Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206829Orig1s000PharmR.pdf.
17. Rashid MU, Rosenborg S, Panagiotidis G, Lofdal KS, Weintraub A, Nord CE. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents. 2015;46(1):60-5. doi: 10.1016/j.ijantimicag.2015.02.027. PubMed PMID: 25979639.
18. Perez F, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ. Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2011;55(6):2585-9. doi: 10.1128/AAC.00891-10. PubMed PMID: 21422202; PMCID: PMC3101444.
19. Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, Hutton RA, Fox WR, Hall GS, Jacobs MR, Paterson DL, Rice LB, Jenkins SG, Tenover FC, Bonomo RA. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother. 2008;52(7):2680-2. doi: 10.1128/AAC.00158-08. PubMed PMID: 18426899; PMCID: PMC2443894.
20. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, Diekema DJ, Hall GS, Jenkins SG, Rice LB, Tenover FC, Bonomo RA. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009;63(3):427-37. doi: 10.1093/jac/dkn547. PubMed PMID: 19155227; PMCID: PMC2640158.
21. Wayne PA. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: CLSI; 2011 [cited 32(3) M100-S20].
22. Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis. 1999;180(2):384-90. doi: 10.1086/314874. PubMed PMID: 10395853.
23. Bergan T, Nord CE, Thorsteinsson SB. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis. 1991;10(6):524-7. doi: 10.1007/BF01963943. PubMed PMID: 1915390.
24. Panagiotidis G, Backstrom T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54(5):1811-4. doi: 10.1128/AAC.01716-09. PubMed PMID: 20231399; PMCID: PMC2863678.
25. Kundrapu S, Sunkesula VC, Jury LA, Cadnum JL, Nerandzic MM, Musuuza JS, Sethi AK, Donskey CJ. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization? BMC Infect Dis. 2016;16(1):159. doi: 10.1186/s12879-016-1514-2. PubMed PMID: 27091232; PMCID: PMC4835867.
26. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother. 2009;53(10):4133-7. doi: 10.1128/AAC.00252-09. PubMed PMID: 19667292; PMCID: PMC2764230.